Tthe U.S. Food and Drug Administration (FDA) has granted approval to WAINUA™ (eplontersen), a pioneering therapy for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) in adults. This regulatory milestone is anchored in the compelling data from the Phase 3 NEURO-TTRansform study. WAINUA™ emerges as the first and only FDA-approved treatment for hATTR-PN that patients can self-administer using an auto-injector. The efficacy of WAINUA™, as evidenced in the study’s findings published in The Journal of the American Medical Association (JAMA), demonstrates its consistent impact in arresting the progression of neuropathic disease and enhancing patient-reported outcomes related to neuropathy impairment and overall quality of life.
This FDA approval marks a crucial milestone in treating rare, debilitating diseases. WAINUA™’s introduction is particularly significant, considering the urgent need for effective treatments in the realm of rare neurological disorders. Its self-administered format via an auto-injector not only enhances ease of use but also empowers patients in managing their treatment. The success of WAINUA™ is a testament to the relentless pursuit of innovation in addressing challenging medical conditions.
Looking beyond hATTR-PN, the potential of WAINUA™ extends to other related conditions. Notably, a large-scale Phase 3 CARDIO-TTRansform study is currently underway for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a condition impacting the heart and typically leading to progressive heart failure. This study, the largest in this patient population to date, is set to provide further insights into the broader applicability of eplontersen, potentially opening new avenues for treatment in related diseases.
The FDA’s endorsement of WAINUA™ for hATTR-PN treatment heralds a new era in the management of rare neuron diseases, showcasing the power of targeted genetic therapies. As WAINUA™ becomes available to patients, it stands as a beacon of hope, not only for those battling hATTR-PN but also for the wider community affected by similar genetic disorders. This approval is a crucial step forward in the ongoing journey to provide more effective, patient-centered treatments for complex, rare diseases.
Related News
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Related Services
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE
AAV cGMP Manufacturing
READ MORE
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE
